Two Smaller Companies Worthy of Your "Attention" [Yahoo! Finance]
Precipio, Inc. (PRPO)
US:NASDAQ Investor Relations:
precipiodx.com/investors.html
Company Research
Source: Yahoo! Finance
Elite Pharmaceuticals Inc. recently received FDA approval for its generic version of Vyanse and expects to launch the product in early 2025. Image Source: Zacks Investment Research Adults as well as women and girls are increasingly being diagnosed with ADHD globally as the medical community continues to understand the symptoms calculus along the neurodivergent spectrum. And medications have proven highly effective in treating ADHD. Recent press coverage on this topic is noteworthy. Also noteworthy are the supply challenges facing ADHD drug producers and the recent raising of production quotas by the DEA. The company has publicly stated that it estimates that it has a greater than 10% share of the Adderall market. The bet here is that the company can duplicate this growth success with its generic version of Vynase. Elite Pharmaceuticals (ELTP) reported revenues of $18.9 million for the three months ended Sept. 30, 2024, marking a 33.4% year-over-year increase. This robust growt
Show less
Read more
Impact Snapshot
Event Time:
PRPO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRPO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRPO alerts
High impacting Precipio, Inc. news events
Weekly update
A roundup of the hottest topics
PRPO
News
- Precipio Inc (PRPO) Q3 2024 Earnings Call Highlights: Strong Growth in Diagnostic Services and ... [Yahoo! Finance]Yahoo! Finance
- Precipio Third Quarter 2024 Earnings: US$0.42 loss per share (vs US$1.04 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- Precipio Announces Q3-2024 Shareholder Update CallGlobeNewswire
- Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation SubtypingGlobeNewswire
PRPO
Sec Filings
- 12/13/24 - Form 4
- 12/11/24 - Form 144
- 11/12/24 - Form 4
- PRPO's page on the SEC website